Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study

被引：0
作者：
Lai Wei
Qing Xie
Jin Lin Hou
Hong Tang
Qin Ning
Jun Cheng
Yuemin Nan
Lunli Zhang
Jun Li
Jianning Jiang
Brian McNabb
Fangqiu Zhang
Gregory Camus
Hongmei Mo
Anu Osinusi
Diana M. Brainard
Guozhong Gong
Zhuangbo Mou
Shanming Wu
Guiqiang Wang
Peng Hu
Yanhang Gao
Jidong Jia
Zhongping Duan
机构：
[1] Peking University People’s Hospital,Beijing Key Lab for Hepatitis C and Immunologic Liver Disease, Peking University Hepatology Institute
[2] Shanghai Jiaotong University,Ruijin Hospital
[3] Nanfang Hospital of Southern Medical University,West China Hospital
[4] Sichuan University,Tongji Hospital of Tongji Medical College
[5] Huanzhong University of Science and Technology,Beijing Friendship Hospital
[6] Beijing Ditan Hospital Affiliated to Capital Medical University,Beijing You
[7] The Third Hospital of Hebei Medical University,An Hospital
[8] The First Affiliated Hospital of Nanchang University,undefined
[9] The First Affiliated Hospital with Nanjing Medical University,undefined
[10] The First Affiliated Hospital of Guangxi Medical University,undefined
[11] Gilead Sciences,undefined
[12] Inc.,undefined
[13] The Second Xiangya Hospital of Central South University,undefined
[14] Jinan Infectious Disease Hospital,undefined
[15] Clinical Center of Shanghai Public Health,undefined
[16] Peking University First Hospital,undefined
[17] The Second Affiliated Hospital of Chongqing Medical University,undefined
[18] The First Hospital of Jilin University,undefined
[19] Capital Medical University,undefined
[20] Capital Medical University,undefined
来源：
Hepatology International | 2018年 / 12卷
关键词：
China; Genotype 1; Hepatitis C virus; Ledipasvir; Sofosbuvir; Single-tablet regimen;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：126 / 132
页数：6
相关论文
共 118 条
[1]  
Polaris Observatory HCVC(2017)Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study Lancet Gastroenterol Hepatol 2 161-176
[2]  
H-y Rao(2017)Real-world treatment patterns and clinical outcomes of HCV treatment-naive patients in China: an interim analysis from the CCgenos study J Gastroenterol Hepatol 32 244-252
[3]  
Li H(2016)APASL consensus statements and recommendation on treatment of hepatitis C Hep Intl 10 702-726
[4]  
Chen H(2016)A Phase 3, open-label study of daclatasvir plus asunaprevir in asian patients with chronic hepatitis C virus genotype 1b infection who are Ineligible for or Intolerant to interferon Alfa therapies with or without ribavirin J Gastroenterol Hepatol 31 1860-1867
[5]  
Shang J(2014)Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Engl J Med 370 1483-1493
[6]  
Xie Q(2014)Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 1889-1898
[7]  
Gao Z-L(2014)Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis N Engl J Med 370 1879-1888
[8]  
Li J(2017)Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection Hepatology 65 1094-1103
[9]  
Omata M(2016)Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response Gastroenterology 151 e1135-413
[10]  
Kanda T(1934)The use of confidence or fiducial limits illustrated in the case of the binomial Biometrika 26 404-1269
12345678910